Artal Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q3 | – | Hold |
0
| – | – | – | 103 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 105 |
|
|
2019
Q1 | – | Hold |
0
| – | – | – | 102 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 99 |
|
|
2018
Q1 | – | Sell |
-250,000
| Closed | -$19.4M | – | 110 |
|
|
2017
Q4 | $19.4M | Sell |
250,000
-150,000
| -38% | -$11.6M | 0.29% | 11 |
|
|
2017
Q3 | $24.5M | Sell |
400,000
-150,000
| -27% | -$9.19M | 0.42% | 9 |
|
|
2017
Q2 | $25.3M | Buy |
550,000
+225,000
| +69% | +$10.4M | 0.44% | 8 |
|
|
2017
Q1 | $14.1M | Buy |
325,000
+175,000
| +117% | +$7.58M | 0.31% | 13 |
|
|
2016
Q4 | $5.81M | Buy |
150,000
+50,000
| +50% | +$1.94M | 0.13% | 26 |
|
|
2016
Q3 | $5.06M | Buy |
100,000
+5,000
| +5% | +$253K | 0.1% | 32 |
|
|
2016
Q2 | $4.32M | Buy |
+95,000
| New | +$4.32M | 0.09% | 30 |
|